Johnson & Johnson news

   Watch this stock
Showing stories 1 - 10 of about 118   

Articles published

JNJ 104.58 +0.03 (0.03%)
price chart
Johnson & Johnson to Quicken Development of Ebola Virus Vaccine
"The decision to accelerate the program is based on the fact that it is such a catastrophic situation in West Africa," said Dr.
Johnson & Johnson Pushes Ahead With Ebola Vaccine  NPR (blog)
Johnson & Johnson (JNJ) to Accelerate Development of Ebola Vaccine  InvestorGuide
Related articles »  
Weekly Pharma Notes: Bristol-Myers Squibb, Johnson & Johnson, Merck And ...
Johnson & Johnson recently stated that it is accelerating the development of a vaccine against the Zaire strain of the Ebola Virus that has been responsible for the current outbreak in Africa.
Related articles »  
Is It Time to Buy Johnson & Johnson's Stock?
A common belief among investors is that it can be considerably tougher for megacap blue-chip companies to double compared to small-caps stocks.
Related articles »  
Johnson & Johnson to Seek Buyer for Cordis Medical-Device Unit
The sales process for the business, called Cordis, is at an early stage, the people said. The business, which could fetch between $1.5 billion and $2 billion, is expected to attract interest from private-equity firms and other health-care companies ...
Johnson & Johnson to seek buyer for medical device maker unit: WSJ  Reuters
Johnson & Johnson Said Exploring Sale of Cordis Devices Business  Bloomberg
Related articles »  
Johnson & Johnson vs. Abbott Laboratories in the Battle for Emerging Market Turf
Based on my 8 rules of dividend investing (more on that below), Abbott Laboratories has the advantage, but Johnson & Johnson is a fantastic company as well. Both businesses make excellent investments for long-term oriented shareholders seeking rising ...
Related articles »  
Johnson & Johnson Should Ignore Those Breakup Calls
Still, there are plenty of investors calling for Johnson & Johnson to break itself up into smaller pieces, even though the company is posting 9% year-over-year revenue growth.
Short Interest in Johnson & Johnson Decreases By 13.2% (JNJ)  Mideast Time
Related articles »  
Medivation Inc's FDA Approval Could be the Deathblow for Johnson & Johnson's ...
Johnson & Johnson's (NYSE: JNJ ) sold over $1 billion worth of its prostate cancer drug Zytiga in the first half of the year, putting it on pace to be a blockbuster two times over .
Medivation's Xtandi Approved For Pre-Chemo Use; Will Compete With ...  Bidness ETC
Pre-chemo nod for Medivation's Xtandi sets up showdown with J&J' ...  FiercePharma
Related articles »  
Dow Jones (DJIA) Today: Johnson & Johnson (JNJ) Leads The Day Higher ...
The Dow component that led the way higher today was Johnson & Johnson (NYSE: JNJ), which sported a three-cent gain to $104.58.
Related articles »  
Johnson & Johnson Seems Expensive Relative To Historical Valuation Metrics ...
However, recall that Johnson & Johnson's expected future earnings growth rate is higher than it has been in the previous several years, so that factor helps explain this elevated valuation.
Related articles »  
Interesting January 2015 Stock Options for Johnson & Johnson
Consistently, one of the more popular stocks people enter into their stock options watchlist at Stock Options Channel is Johnson & Johnson JNJ +0.03% (NYSE: JNJ). So this week we highlight one interesting put contract, and one interesting call contract ...
Related articles »